Dose-reduced fludarabine, cyclophosphamide and rituximab (FCR) in older patients with chronic lymphocytic leukemia: does one size fit all?

References

• Molica S. Sex differences in incidence and outcome ofchronic lymphocytic leukemia patients. Leuk Lymphoma. 2006;47:1477–1480.
   PubMed Web of Science ®Google Scholar
• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265–276.
   PubMed Web of Science ®Google Scholar
• Watson L, Wyld P, Catovsky D. Disease burden of chronic lymphocytic leukaemia within the European Union. Eur J Haematol. 2008;81:253–258.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370:1101–1110.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Engelke A, et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015;29:1602–1604.
   PubMed Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. NEngl J Med. 2014;370:997–1007.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015;385:1873–1883.
   PubMed Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425–2437.
   PubMed Web of Science ®Google Scholar
• Michallet AS, Aktan M, Schuh A, et al. Rituximab in combination with bendamustine or chlorambucil for the treatment of chronic lymphocytic leukemia: primary results from the randomised phase IIIb MABLE study. Leuk Lymphoma (Suppl). 2015.
   Google Scholar
• Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968;16:622–626.
   PubMed Web of Science ®Google Scholar
• Parmelee PA, Thuras PD, Katz IR, et al. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc. 1995;43:130–137.
   PubMed Web of Science ®Google Scholar
• Fischer K, Bahlo J, Fink AM, et al. Long term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127:208--215.
   PubMed Web of Science ®Google Scholar
• Tam CS, O'Brien S, Plunkett W, et al. Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood. 2014;124:3059–3064.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Bosch F, et al. Updated survival analysis from the CLL11 study: obinutuzumab versus rituximab in chemoimmunotherapy-treated patients with chronic lymphocytic leukemia. Blood (Suppl). 2015.
   Google Scholar
• Eichhorst B, Fink AM, Busch R, et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL study group (GCLLSG) (CLL10 Study). Blood (Suppl). 2014;124(21).
   Google Scholar
• Shanafelt T, Lanasa MC, Call TG, et al. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). Cancer. 2013;119:3788–3796.
   PubMed Web of Science ®Google Scholar
• Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27:498–503.
   PubMed Web of Science ®Google Scholar
• Foon KA, Mehta D, Lentzsch S, et al. Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia. Blood. 2012;119:3184–3185.
   PubMed Web of Science ®Google Scholar
• Caroline Dartigeas EVDN, Berthou C, Maisonneuve H, et al. Safety and efficacy of abbreviated induction with oral fludarabine (F) and cyclophosphamide (C) combined with dose-dense IV rituximab (R) in previously untreated patients with chronic lymphocytic leukemia (CLL) aged >65 years: results of a multicenter trial (LLC 2007 SA) on behalf of the French Goelams/Fcgcll-WM Intergroup. Blood. 2012;120 :Abstract 434.
   Google Scholar
• Nikitin E, Kisilichina D, Zakharov O, et al. Randomised comparison of FCR-lite and CLR (chlorambucil plus rituximab) regimens in elderly patients with chronic lymphocytic leukemia. Haematologica (Suppl). 2013.
   Google Scholar
• Mato AR, Foon KA, Feldman T, et al. Reduced-dose fludarabine, cyclophosphamide and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia. Am J Hematol. 2015;90:487--492.
   PubMed Web of Science ®Google Scholar
• Smolej LBY, Doubek M, Cmunt E, et al. Low-dose FCR is a safe and effective treatment option for elderly/comorbid patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Updated results of project Q-lite by Czech CLL study group. Blood. 2014;124 :Abstract 4670.
   PubMed Web of Science ®Google Scholar
• Mulligan SG,D, Turner PW, Latimer M, et al. A randomised dose de-escalation study of oral fludarabine, ±oral cyclophosphamide and intravenous rituximab as first-line therapy of fit patients with chronic lymphocytic leukaemia (CLL) aged ≥65 years: final analysis of response and toxicity. Blood. 2014;124 :Abstract 3325.
   PubMed Web of Science ®Google Scholar
• Lew TE, Cheah CY, Carney DA, et al. Dose reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy. Leuk Lymphoma. 2016;57:1044--1053.
   PubMed Web of Science ®Google Scholar
• Bouvet E, Borel C, Oberic L, et al. Impact of dose intensity on outcome of fludarabine, cyclophosphamide, andrituximab regimen given in the first-line therapy for chronic lymphocytic leukemia. Haematologica. 2013;98:65–70.
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Goldschmidt N, Bairey O, et al. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximabregimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience. Haematologica. 2015;100:662–669.
   PubMed Web of Science ®Google Scholar
• Kovacs G, Bahlo J, Kluth S, et al. Prognostic impact and risk factors of reducing prescribed doses of fludarabine, cyclophosphamide and rituximab (FCR) during frontline treatment of chronic lymphocytic leukemia (CLL). Blood (Suppl). 2015;126:Abstract 4156.
   Google Scholar
• Fischer K, Fink AM, Bishop H, et al. Results of thesafety run-in phase of CLL14 (BO25323): a prospective, open-label, multicenter randomized phase III trial to compare the efficacy and safety of obinutuzumab and venetoclax (GDC-0199/ABT-199) with obinutuzumab and chlorambucil in patients with previously untreated CLL and coexisting medical conditions clinically relevant abstract. Blood (Suppl). 2015;126:Abstract 496.
   Google Scholar